Company intelligence / Profile preview

TAVO103A developers

Lower Gwynedd, Pennsylvania, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Tavotek Biotherapeutics is a clinical-stage biotechnology company focused on developing next-generation multi-specific antibodies for oncology and autoimmune diseases. The company utilizes its proprietary TAVO-Plus, TAVO-Precise, and TAVO-Select platforms to engineer biologics with enhanced efficacy and safety profiles. Its lead candidate, TAVO103A, is a trispecific antibody targeting PD-L1 and CD137 while utilizing human serum albumin for extended half-life. Tavotek aims to address unmet medical needs by creating differentiated therapies that modulate the immune system more effectively than traditional monoclonal antibodies.

Therapeutic areas: OncologyImmunology
Modalities: AntibodyTrispecific antibodyBiologicMulti-specific antibody
Industry: Biotech

Beyond the preview

Go deeper on TAVO103A developers.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAVO103A developers.

Explore the full profile